Are peptides a treatment for long COVID?

Short answer: no. As of July 2026 there is no peptide that counts as an approved or proven treatment for long COVID, and the same is true of every other class of medicine, because no drug has been approved specifically for the condition at all. Some peptides have been examined in COVID research, but almost all of that work looked at acute, hospital-stage infection or was done in animals, not in people living with long COVID. The one randomized peptide trial run in a post-COVID condition studied a different illness, in young children, in only a dozen patients. This page lays out, source by source, exactly what has and has not been shown, so you can weigh the online claims against the actual evidence.

Are peptides a treatment for long COVID?

No peptide is an approved or proven treatment for long COVID, and the honest version of the answer is that no reliable evidence exists that any of them fixes the condition in people. Long COVID is not a single, simple illness: the U.S. Centers for Disease Control and Prevention describes it as “a chronic condition that occurs after SARS-CoV-2 infection and is present for at least 3 months,” spanning a wide range of symptoms that can come and go over months or years. The peptides most often promoted for it online, chiefly BPC-157 and thymosin alpha-1, have never been tested against long COVID in a rigorous human trial. What exists is a mix of laboratory theory, animal work, and studies of acute infection, which is a very different thing from evidence that a peptide relieves post-COVID fatigue, brain fog, or dysautonomia. Treat any confident “peptides treat long COVID” claim as marketing that runs ahead of the science.

Is any drug approved or proven for long COVID in 2026?

No medicine is approved specifically for long COVID as of 2026, which is the single most important piece of context for the peptide question. When the National Institutes of Health launched its long COVID treatment trials through the RECOVER Initiative, a “$1.15 billion effort,” it did so precisely because the condition, which it says affects “the millions of people living with long COVID” and “presents with more than 200 symptoms,” still has no established therapy. Those government-funded trials began with repurposed options such as an extended course of the antiviral Paxlovid, and a follow-on round, RECOVER-TLC, has since advanced candidates including the anti-inflammatory drug baricitinib, low-dose naltrexone, and a GLP-1 receptor agonist. A GLP-1 receptor agonist is itself a peptide, which is the useful distinction to draw: it is a studied, physician-supervised medicine rather than a vial sold as “research use only,” and none of the peptides marketed online for gut and immune health is among the candidates these trials chose to test. The early results are also sobering: in a randomized trial, an extended 15-day course of Paxlovid did not relieve long COVID symptoms better than placebo. The takeaway is not that treatment is hopeless, but that even well-resourced trials of mainstream drugs are still searching for something that works, so a peptide bought online is not quietly succeeding where a billion-dollar research program has not yet landed.

What does the research on BPC-157 and COVID actually show?

The most-cited BPC-157-and-COVID paper is a hypothesis article, not a clinical trial, and it is about acute COVID rather than long COVID. Published in the journal Medical Hypotheses in 2022, it argues that because COVID-19 behaves partly as a blood-vessel and clotting disease, BPC-157’s anti-inflammatory and blood-vessel-protective properties could in theory be worth studying as a complementary approach. Crucially, the author reports no human COVID data and is explicit about the gap, writing that “the majority of studies are predominantly limited to mostly animal models and the efficacy of BPC 157 in humans has not been explored extensively.” The paper’s own conclusion is that “all examined treatments, although potentiality effective against COVID-19, need either appropriate drug development or clinical trials in humans to be suitable for clinical use.” In plain terms: a researcher proposed a mechanism and called for trials that, as of 2026, still have not been run in long COVID. A published hypothesis is a reason to investigate, not evidence that the peptide helps.

Has thymosin alpha-1 been studied in people with COVID?

Thymosin alpha-1 has been studied in COVID patients, but the research is in acute, hospitalized infection, it is retrospective rather than randomized, and the results conflict. One multicenter retrospective cohort study of critically ill patients in China, published in International Immunopharmacology in 2020, reported that “treatment with thymosin α1 significantly reduced 28-day mortality (Hazards Ratios HR, 0.11, 95% CI 0.02–0.63, P=0.013)” in the sickest patients, while cautioning that “further study is needed to investigate the underlying mechanisms, dosage and duration of thymosin α1 therapy”. A separate propensity-matched analysis of 1,388 non-severe patients found the opposite for its main outcomes: thymosin alpha-1 “did not prevent COVID-19 progression and reduce COVID-19-related mortality rate,” with mortality of 0.54% versus 0% in controls (p = 0.317) and progression to severe disease of 2.17% versus 2.71% (p = 0.736). None of these studies looked at long COVID, and thymosin alpha-1 is not approved by the FDA in the United States. So even where a signal appears, it is an acute-infection, hospital-setting signal from non-randomized data, not proof of anything for post-COVID recovery.

What about larazotide, the one peptide trialed in a post-COVID condition?

There is exactly one randomized peptide trial in a post-COVID condition, and reading it carefully shows why it does not answer the long-COVID question. Reported in Science Translational Medicine in 2025, it was a phase 2a randomized, double-blind, placebo-controlled trial of larazotide in 12 children with multisystem inflammatory syndrome in children (MIS-C), a rare, acute, post-infectious illness with a median patient age under six. Treated children showed “faster clearance of spike antigen,” “faster resolution of gastrointestinal symptoms,” and “faster return to usual activities,” with no larazotide-related adverse events during follow-up, which is a genuinely encouraging early result for that specific syndrome. But three caveats matter. MIS-C is not the same illness as the fatigue-and-brain-fog long COVID most adults mean; the trial enrolled only a dozen patients at an early phase; and larazotide is an investigational drug developed for celiac disease, not one of the “wellness” peptides sold in vials online. It is a promising lead in a narrow pediatric setting, not a green light for self-treating long COVID with peptides.

What is known about BPC-157 safety in people?

Very little, which matters more than any single study above. The U.S. Department of Defense’s Operation Supplement Safety program summarizes the human record bluntly: “there is little to no reliable scientific evidence to support the safety or effectiveness of BPC-157 in humans.” That is a statement about missing data, not proof of harm, but it means nobody can tell a person with long COVID what side effects to expect, how the peptide interacts with their other medicines, or whether it is wise alongside an ongoing illness. Someone already dealing with fatigue, autonomic symptoms or gut trouble has less room than most to absorb an unexpected reaction, so that gap is worth weighing before anything else.

What are people saying about peptides and long COVID?

On social media, BPC-157 is discussed mainly as a gut-repair and tissue-repair peptide rather than as a long-COVID remedy. Our Community Insights summary for BPC-157 on this site analyzed 16 public posts on X from July 16 to 20, 2026, and the themes below summarize that discussion; they are anecdotes, not evidence.

• Gut repair is the main use people describe. Posters most often say they take oral BPC-157 to repair the gut lining or for what they call leaky gut, and they do not agree on how much it helps.
• Safety is contested. One poster reports finding roughly 20 self-reported cancer-like adverse events and points to the peptide’s VEGF activity as a reason for caution, while stressing that nobody knows how many people used it. Others describe it as cheap and low-risk.
• No long-COVID evidence is cited. None of the themes in that sample tie BPC-157 to a long-COVID outcome, which matches the research record above.

What is a sensible next step if you have long COVID?

Start with a licensed clinician and evidence-guided care for your specific symptoms. Long COVID is real and can be genuinely disabling, and the most useful path is a medical evaluation that maps your particular pattern, whether that is fatigue, post-exertional malaise, autonomic symptoms, or gut issues, onto the care that has evidence behind it and someone responsible for your safety. That can include symptom-directed treatment, structured rehabilitation where appropriate, management of specific complications, and, for eligible patients, enrollment in a registered clinical trial through a program like NIH RECOVER. If you are curious about a peptide, bring it to that conversation rather than trying it alone, since there is no human long-COVID data to guide the choice. For related reading, see our checklist of questions to ask your doctor about peptides and what the research on BPC-157 and gut health actually shows.

Status: BPC-157: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. Thymosin alpha-1: Not FDA-approved; sold by some telehealth providers as a compounded prescription. What these status terms mean.

Educational information only, not medical advice. Every scientific statement here is sourced to the primary literature, the CDC and NIH, and U.S. Department of Defense safety guidance cited above; the research summary reflects sources checked on July 12, 2026, and the status line reflects the network status page as of October 12, 2026. Long COVID care should be individualized with a licensed clinician.